Publicacions destacades

• Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

  Villacampa, G; Tung, N M; Pernas, S; Pare, L; Bueno-Muino, C;

  (...)

  Carey, L A; Mittendorf, E A; Martin, M; Prat, A; Tolaney, S M.

  Veure llistat complet d'autors

  Referència:

  Annals Of Oncology 2023.

• An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)

  Prat, A; Bardia, A; Curigliano, G; Hammond, MEH; Loibl, S;

  Tolaney, SM; Viale, G.

  Referència:

  Jama Oncology 2022.

• Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

  Prat, Aleix; Guarneri, Valentina; Pascual, Tomas; Braso-Maristany, Fara; Sanfeliu, Esther;

  (...)

  Vivancos, Ana; Villagrasa, Patricia; Parker, Joel S; Conte, Pierfranco; Perou, Charles M.

  Veure llistat complet d'autors

  Referència:

  Ebiomedicine 2022.

• Customizing local and systemic therapies for women with early breast cancer: the st. gallen international consensus guidelines for treatment of early breast cancer 2021

  H J Burstein; G Curigliano; B Thürlimann; W P Weber; P Poortmans 5;

  M M Regan; H J Senn; E P Winer; M Gnant; Panelists of the St Gallen Consensus Conference.

  Referència:

  Ann Oncol. 2021.

• Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

  Prat, A; Chaudhury, A; Solovieff, N; Paré, L; Martinez, D;

  (...)

  Brasó-Maristany, F; Lteif, A; Taran, T; Babbar, N; Su, F.

  Veure llistat complet d'autors

  Referència:

  Journal Of Clinical Oncology 2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

  (...)

  Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

  Veure llistat complet d'autors

  Referència:

  Lancet Oncology 2020.

• Frequency and spectrum of PIK3CA somatic mutations in breast cancer

  Martinez-Saez, Olga; Chic, Nuria; Pascual, Tomas; Adamo, Barbara; Vidal, Maria;

  (...)

  Galvan, Patricia; Rodriguez, Ana Belen; Martinez, Antonio; Munoz, Montserrat; Prat, Aleix.

  Veure llistat complet d'autors

  Referència:

  Breast Cancer Research 2020.

• Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

  Brasó-Maristany F.; Griguolo G.; Pascual T.; Paré L.; Nuciforo P.;

  (...)

  Gomis R.R.; Villagrasa P.; Cortés J.; Ciruelos E.; Prat A..

  Veure llistat complet d'autors

  Referència:

  Nature Communications 2020.

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  Prat A; Saura C; Pascual T; Hernando C; Muñoz M;

  (...)

  López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J .

  Veure llistat complet d'autors

  Referència:

  Lancet Oncology 2020.